Chapman University

Chapman University Digital Commons
Pharmacy Faculty Articles and Research

School of Pharmacy

4-21-2022

Bis-Cinnamamide Derivatives as APE/Ref-1 Inhibitors for the
Treatment of Human Melanoma
Razan Alhazmi
Shirley Tong
Shaban Darwish
Elina Khanjani
Bharti Khungar

See next page for additional authors

Follow this and additional works at: https://digitalcommons.chapman.edu/pharmacy_articles
Part of the Amino Acids, Peptides, and Proteins Commons, Cancer Biology Commons, Medicinal and
Pharmaceutical Chemistry Commons, and the Other Pharmacy and Pharmaceutical Sciences Commons

Bis-Cinnamamide Derivatives as APE/Ref-1 Inhibitors for the Treatment of
Human Melanoma
Comments
This article was originally published in Molecules, volume 27, in 2022. https://doi.org/10.3390/
molecules27092672

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

Copyright
The authors

Authors
Razan Alhazmi, Shirley Tong, Shaban Darwish, Elina Khanjani, Bharti Khungar, Swati Chawla, Zhonghui
Zheng, Richard Chamberlain, Keykavous Parang, and Sun Yang

molecules
Article

Bis-Cinnamamide Derivatives as APE/Ref-1 Inhibitors for the
Treatment of Human Melanoma
Razan Alhazmi 1,† , Shirley Tong 1,† , Shaban Darwish 1,‡ , Elina Khanjani 1 , Bharti Khungar 1,§ , Swati Chawla 1 ,
Zhonghui Zheng 2 , Richard Chamberlin 2 , Keykavous Parang 1, * and Sun Yang 3, *
1

2

3

*
†
‡
§

Citation: Alhazmi, R.; Tong, S.;
Darwish, S.; Khanjani, E.; Khungar,
B.; Chawla, S.; Zheng, Z.;
Chamberlin, R.; Parang, K.; Yang, S.
Bis-Cinnamamide Derivatives as
APE/Ref-1 Inhibitors for the
Treatment of Human Melanoma.
Molecules 2022, 27, 2672. https://
doi.org/10.3390/molecules27092672
Academic Editor: Fengqing Yang
Received: 8 March 2022
Accepted: 18 April 2022
Published: 21 April 2022
Publisher’s Note: MDPI stays neutral

Center for Targeted Drug Delivery, Department of Biomedical and Pharmaceutical Sciences,
Chapman University School of Pharmacy, Irvine, CA 92618, USA; alhaz101@mail.chapman.edu (R.A.);
fong149@mail.chapman.edu (S.T.); shaban_darwish@yahoo.com.sg (S.D.); bsharifi@chapman.edu (E.K.);
bkhungar@pilani.bits-pilani.ac.in (B.K.); chawlaswati@hotmail.com (S.C.)
Department of Pharmaceutical Sciences, University of California Irvine, Irvine, CA 92697, USA;
zhengzhonghui@sina.com (Z.Z.); richard.chamberlin@uci.edu (R.C.)
Department of Pharmacy Practice, Chapman University School of Pharmacy, Irvine, CA 92618, USA
Correspondence: parang@chapman.edu (K.P.); syang@chapman.edu (S.Y.); Tel.: +1-(714)-516-5489 (K.P.);
+1-(714)-516-5418 (S.Y.)
These authors contributed equally to this work.
Current address: Organometallic and Organometalloid Chemistry Department, National Research Centre,
El Bohouth St, Dokki, Giza 12622, Egypt.
Current address: Department of Chemistry, Birla Institute of Technology & Science, Pilani 333031, India.

Abstract: Human malignant melanoma exhibits imbalances in redox status, leading to activation
of many redox-sensitive signaling pathways. APE/Ref-1 is a multifunctional protein that serves
as a redox chaperone that regulates many nuclear transcription factors and is an important mechanism in cancer cell survival of oxidative stress. Previous studies showed that APE/Ref-1 is a
potential druggable target for melanoma therapy. In this study, we synthesized a novel APE/Ref-1
inhibitor, bis-cinnamoyl-1,12-dodecamethylenediamine (2). In a xenograft mouse model, compound
2 treatment (5 mg/kg) significantly inhibited tumor growth compared to the control group, with
no significant systemic toxicity observed. We further synthesized compound 2 analogs to determine the structure-activity relationship based on their anti-melanoma activities. Among those,
4-hydroxyphenyl derivative (11) exhibited potent anti-melanoma activities and improved water
solubility compared to its parental compound 2. The IC50 of compound 11 was found to be less than
0.1 µM. Compared to other known APE/Ref-1 inhibitors, compound 11 exhibited increased potency
in inhibiting melanoma proliferation. As determined by luciferase reporter analyses, compound 2
was shown to effectively inhibit H2 O2 -activated AP-1 transcription activities. Targeting APE/Ref-1mediated signaling using pharmaceutical inhibitors is a novel and effective strategy for melanoma
treatment with potentially high impact.
Keywords: APE/Ref-1; human melanoma; small molecular inhibitors; reactive oxygen species (ROS);
redox regulation
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Melanoma arising from melanocytes makes up only 2% of all skin cancers, while it
causes over 80% of all skin cancer deaths [1]. In recent years, melanoma incidence rates have
increased more rapidly than other cancer types in the United States, and it is expected that
7650 patients will die due to melanoma in 2022 alone [2]. Ultraviolet radiation (UVR,) which
can generate reactive oxygen species (ROS) and nitric oxide (NO) in the skin [3–5], has been
implicated as a significant environmental contributor to the development of melanoma [6,7].
The contributions of UVR to melanomagenesis and malignant development may, at least
partially, be due to ROS- or NO-induced DNA damage, which has been studied in our
laboratory and by other groups [8–11].
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APE/Ref-1 is a critical enzyme in DNA base excision repair, which catalyzes the
cleavage of the phosphodiester bond at either the 50 or 30 end of an apurinic/apyrimidinic
site [12]. Studies have also revealed that APE-1 exhibits distinct redox functions that
facilitate DNA binding activities of many nuclear transcription factors (such as AP-1,
Myb, NF-κB, p53, and HIF-α); due to its redox-regulatory activity, it is also known as
Redox Factor-1 (Ref-1) [13]. APE/Ref-1 plays a critical role in malignant transformation
when combined with elevated ROS levels in the JB6 model [14]. Notably, our previous
studies demonstrated that APE/Ref-1 is induced by ROS and NO stress [8,15]. In addition,
genome-wide analyses and proteomic studies also suggest an important role of APE/Ref-1
in regulating many biological processes, such as mitochondrial function and ribosomal
RNA quality control [16].
Accumulating evidence shows that many human tumors, including the brain, cervical,
and prostate cancers, exhibit elevated APE/Ref-1 expression and abnormal subcellular
localization compared to normal tissues, making it an attractive druggable target for developing new cancer therapeutic strategies [12,17,18]. Up-regulated APE/Ref-1 is shown to
protect cells from various pro-apoptosis stimuli, including oxidative stresses, chemotherapeutic drugs, and radiation treatment [19,20]. Elevated APE/Ref-1 has been closely
associated with increased metastasis of cancer cells and contributes to tumor development
and progression in human melanoma and hepatocellular carcinoma [15,21,22]. Compounds
impairing APE/Ref-1-mediated redox signaling or DNA repair have shown enhanced antitumor activities [23–25]; however, other studies have also demonstrated the pro-apoptotic
effects of APE/Ref-1 by potentiating p53-mediated signaling [26]. The experimental stresses
applied in the studies may explain the distinct role of APE/Ref-1 in apoptosis.
In addition, given the complexity of cancer signaling networks, there are wide varieties of
intra- and intercellular signaling pathways that could fuel cancer progression [27]. APE/Ref-1
regulates many nuclear transcription factors in a redox-dependent and -independent manner.
Inhibition of APE/Ref-1 may generate broader inhibition of its regulated signaling network,
compared to blocking a single signaling pathway downstream of APE/Ref-1 [12,28]. Direct
inhibition may be more efficient and minimize the development of drug resistance.
The crystal structure of APE/Ref-1 revealed potentially druggable pockets in the
vicinity of Cys65, which is located in the redox regulation domain. The studies showed
that redox-specific inhibition of APE/Ref-1 induced cell cycle arrest and sensitized cancer
cells to chemotherapy [28–32]. We have conducted virtual screenings using the ICM
software package developed by Molsoft [33–35], which docks small molecules from a large
database and ranks binding affinity using an energetic scoring function. The chemical
structures of the top hit compounds were identified [15], and a series of analogs based
on the lead compound structure were designed and synthesized in our study. Among
them, bis-cinnamoyl-1,12-dodecamethylenediamine (compound 2) (Figure 1) exhibited
the most potent anti-melanoma activity both in vitro and in vivo. The structure-activity
relationship generated from our study will shed light on the future design and synthesis of
small molecular inhibitors targeting APE/Ref-1 for melanoma treatment.
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Figure 1. Chemical structures of cinnamamide derivatives.

2. Results
2.1. Chemistry
In this study, a series of symmetrical and unsymmetrical dicinnamoyl derivatives conjugated through hydrophobic central units of 1,12-diaminododecane and 1,6-diaminohexane
were synthesized as depicted in Schemes 1 and 2. Different bolaamphiphiles were prepared
based on increasing the hydrophilicity of these compounds by introducing hydrophilic
hydroxyl groups to the aromatic rings and changing the hydrophobic chain length.

Scheme 1. Synthesis of bis-cinnamoyl-1,12-dodecamethylenediamine (2).

First, bis-cinnamoyl-1,12-dodecamethylenediamine (2) was synthesized by the reacting
cinnamoyl chloride (1) with 1,12-dodecamethylenediamine in dry THF in the presence of
potassium carbonate as a base (Scheme 1). The structure of the product was confirmed by
NMR and mass spectrometry. The purity was confirmed by analytical HPLC, showing a
retention time (Rt ) of 26 min.
To improve water solubility, diamide bolaamphiphiles containing two hydroxyl groups
were prepared using N-methylmorpholine (NMM) and 1-[bis(dimethylamino)methylene]1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (Hexafluorophosphate Azabenzotriazole Tetramethyl Uronium, HATU) as a coupling reagent. Symmetrical bolaamphiphile derivatives (4, 5, and 7) were prepared through a coupling reaction of one equivalent of 1,12-dodecamethylenediamine with two equivalents of the cinnamic acid derivative
under basic conditions; 4-Hydroxycinnamic acid (3) and 3-hydroxycinnamic acid (6) were
activated by HATU, followed by a coupling reaction with 1,12-dodecamethylenediamine
in the presence of NMM as a basic catalyst to generate the corresponding diamide, bis-(4hydroxy-cinnamoyl)-1,12-dodecamethylenediamine (4) and bis-(3-hydroxy-cinnamoyl)1,12-dodecamethylenediamine (7), respectively (Scheme 2a,b). Analytical HPLC confirmed
the purity of compounds 4 and 7, showing (Rt ) = 21.89 and 22.19 min, respectively; moreover, to prepare a more hydrophilic bolaamphiphile derivative, a shorter aliphatic 1,6-
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dihexylamine was used for the reaction with compound 3 to prepare bis-(4-hydroxycinnamoyl)-1,6-hexanemethylenediamine (5) under the same conditions, as mentioned
above (Scheme 2a). The crude products were purified by silica gel column chromatography
and the purity was confirmed using analytical HPLC (Supplementary Materials).

Scheme 2. Synthesis of bis-cinnamoyl derivatives. (a) Synthesis of symmetrical bis-cinnamoyl
derivatives 4 and 5; (b) Synthesis of symmetrical bis-cinnamoyl derivative 7 and unsymmetrical
bis-cinnamoyl derivative 9; (c) Synthesis of unsymmetrical bis-cinnamoyl derivative 11; (d) Synthesis
of symmetrical bis-cinnamoyl derivative 12.
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Unsymmetrical bis-cinnamamide derivatives 9 and 11 were synthesized in two steps.
First, the reaction of equimolar amounts of the appropriate acid derivative and the diamine was used to afford the corresponding monocinnamamide. It should be noted that
optimizing the reaction conditions, such as using a mild activating reagent and reaction
time control, was required to drive the reaction towards a single coupling and create the
desired compound containing a free amine group for the subsequent coupling. As depicted in Scheme 2b,c, N-(12-aminododecyl)-3-(3-hydroxyphenyl) acrylamide (8) and N-(12aminododecyl)-cinnamamide (10) were constructed from the reaction of 3-hydroxycinnamic
acid (6) and cinnamic acid (1), respectively, with diamine in the presence of HBTU and
DIPEA over 2 h. As a representative example, the novel monoamide (8) was identified via
mass spectrometry, exhibiting a mass of 347.1 [M + H]+ ; moreover, the 1 H NMR spectra
showed broad singlet and triplet peaks at 7.69 and 8.08 ppm, which are characteristics of
NH2 and NH, respectively. The singlet peak at 9.57 ppm represents the phenolic hydroxyl
group (Figure S13, Supplementary Materials).
Second, using similar conditions as used in the synthesis of compound 4, monocinnamoylfatty acyl amide conjugates (8 and 10) containing free amino groups were reacted with
the additional cinnamic acid derivatives (1 and 3), respectively. As shown in Scheme 2b,c,
these reactions afforded the corresponding unsymmetrical bis-cinnamoyl derivatives, N-(12cinnamamidododecyl)-3-(3-hydroxyphenyl) acrylamide (9) and N-(12-cinnamamidododecyl)3-(4-hydroxyphenyl) acrylamide (11), with each possessing only one hydroxyl group. As a
representative example, the 1 H NMR spectrum fits well with structure 9 and indicated that
the molecule has unsymmetrical imide protons, showing two triplet signals at 7.92 and
8.08 ppm.
Using an alternative method, as shown in Scheme 2d, hexane-1,6-diamine was reacted
with cinnamic acid in the presence of pyridine and triphenyl phosphite for 8 h to afford
(2E,2’E)-N,N’-(Propane-1,3-diyl)bis(3-phenylacrylamide) (12).
2.2. Molecular Docking Study of the Synthesized Compound Candidates
Using molecular modeling, we further evaluated the new compounds by docking the
compounds to the APE/Ref-1 crystal structure, downloaded from PDB (1BIX) (Table 1) [15].
Figure 2 shows the binding of compound 2 into its binding site of APE/Ref-1, resulting
in an ICM docking score of −9.23. Compound 11 docked into the same binding cavity,
with an ICM docking score of −16.31. The best docking score among all the synthesized
candidate compounds was observed with Compound 4 (−20.14), as shown in Table 1.
Table 1. Docking scores and cytotoxicity of compounds in human melanoma A375 and SKMel-28 cells.
Synthesized
Compounds

Docking Score

Anti-Melanoma Activities

2

−9.23

Cytotoxicity is not dose-dependent; at 0.1 µM, cell viability
reduced to <50% of control in A375 cells.

11

−16.31

0.079 ± 0.013 µM (IC50 , detected by MTT assay, average in
two human melanoma cell lines: A375 and SK-Mel-28)

4

−20.14

50% inhibition of cell survival not observed up to 10 µM.

5

−12.91

50% inhibition of cell survival not observed up to 50 µM.

7

−11.74

50% inhibition of cell survival not observed up to 10 µM.

8

−12.51

50% inhibition of cell survival not observed up to 25 µM.

9

−5.97

50% inhibition of cell survival not observed up to 10 µM.

10

−15.44

50% inhibition of cell survival not observed up to 25 µM.

12

−10.06

50% inhibition of cell survival not observed up to 10 µM.
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Figure 2. Molecular docking and binding mode of compound 2 to the druggable binding site of the
APE/Ref-1 protein (1BIX).

2.3. Effects of Novel APE/Ref-1 Inhibitors on Melanoma Proliferation Using MTT
Colorimetric Assay
APE/Ref-1 inhibitors have exhibited anti-proliferation and anti-angiogenesis activity
against several human malignancies; therefore, we have chosen anti-tumor efficacy as an
endpoint to rank the candidate compounds for bio-evaluation. MTT assays were conducted
to evaluate the in vitro anti-melanoma activities of the synthesized compounds in human
melanoma cell lines and immortalized melanocytes. Cells were incubated with compounds
at various concentrations for 72 h. Cell viabilities after treatments were then analyzed in
comparison to that of control.
As shown in Figure 3a, lead compound 2 exhibited potent cytotoxicity in human
melanoma A375 cells at 0.1 µM as the surviving cells were reduced to less than 50% of
control after 72 h treatment; however, with increasing doses, the cellular toxicity was
not increased accordingly in both cell lines, which may be explained by the limited water
solubility and stability of compound 2 (Figure 3a). Apparent drug precipitation was evident
in the media at higher concentrations (≥2.5 µM). Of note, no significant cytotoxicity of
compound 2 was observed among two melanoblast cell lines after 72 h treatment (Hermes
3A and Hermes 4A, Figure 3b). Hermes 1 cells were more sensitive to compound 2, but the
cytotoxicity was not elevated with increasing concentrations.
Compounds 4 and 7 are analogs of lead compound 2 in which two hydrophilic hydroxyl groups (−OH) were added to the aromatic rings. The virtual docking scores of
compounds 4 and 7 analyzed by the ICM-Pro program are −20.14 and −11.74, respectively. Compared to compound 2 (−9.23), compound 4 exhibited improved docking to the
druggable pocket localized in the redox domain of APE/Ref-1; however, the MTT results
showed these modifications led to a significant loss of anti-tumor activity compared to
compound 2.
Similar to compound 4, compound 5 has two hydrophilic groups (−OH) but includes
a modified chain length to increase the water solubility and was found to have a virtual
docking score of −12.91. MTT analysis demonstrated that such modification also resulted
in the loss of anti-melanoma activity compared to compound 2, and 50% cell death was not
observed up to 50 µM (Table 1).
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Compounds 9 and 11 are analogs of lead compound 2, in which one hydrophilic
hydroxyl group (−OH) was added to the meta- or para-position, respectively. The corresponding virtual docking scores of compounds 9 and 11 are −5.97 and −16.31 (Table 1).
Compound 9 showed poor anti-melanoma activity, while compound 11 exhibited a potent
cytotoxic effect in melanoma cells (Figure 3). The virtual docking profiles align well with
their anti-melanoma activities, suggesting the position of the −OH group plays a vital role
in their interactions with the APE/Ref−1 protein. The binding profile model may guide
future modifications of the aromatic ring and predict the compounds’ anti-melanoma activities; moreover, compound 11 exhibits improved water solubility compared to compound 2
due to the hydrophilic hydroxyl group. Significant precipitation was evident at ~20 µM,
approximately 8-folds higher than compound 2 (2.5 µM, data not shown).
2.4. Potent and Selective Anti-Tumor Activities of Compound 11 in Human Melanoma Cells
Among all the synthesized analogs of compound 2, compound 11 exhibited promising anti-tumor activities with improved water solubility in a dose-dependent manner.
The viabilities of melanoma cells were significantly decreased with compound 11 treatment (Figure 3c,d). In comparison to well-studied APE/Ref-1 inhibitors, E2009 and
E3330 [30,31,36], compound 11 exhibited significantly increased potency in reducing viability in melanoma cells (Figure 3c). The IC50 s of compound 11 in A375 and SK-Mel-28
melanoma cells were 0.088 µM and 0.07 µM, respectively (Figure 3d, Table 1), which are
more potent than commercially available APE/Ref-1 redox inhibitors. At 1 µM, cell viability reduced to 19% of control (vehicle only, 0.1% DMSO) after treatment with compound
11, while no significant cytotoxicity was observed with E2009 and E3330 treatment at the
same concentration (96.7% and 102.6% of control, respectively) (Figure 3c). The IC50s of
E3330 and E2009 in A375 melanoma cells were 6.6 µM and 5.3 µM, respectively, which
were 75-fold and 60-fold higher compared to that of compound 11.
The selectivity of compound 11 was also determined by comparing its cytotoxicity
in melanoma cells to that in normal melanoblast Hermes 1 cells. As shown in Figure 3d,
the IC50 of compound 11 in Hermes 1 is 0.274 µM, which is much higher than the IC50s
observed in A375 and SK-Mel-28 melanoma cells.
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Figure 3. Potent cytotoxicity of compounds 2 and 11 in human melanoma cells. Cell viability
was determined by MTT assay. The results are shown as the percentage of viable cells after 72 h
treatment at different concentrations. The results were statistically processed from three independent
experiments. The IC50 was calculated using GraphPad Prism 8. (a) Cytotoxicity of compound 2 in
A375 melanoma cells; (b) Cytotoxicity of compound 2 in human immortalized melanoblasts cells
(Hermes 1, 3A, and 4A). The bars represent the average of three independent experiments. Hermes 1,
Hermes 3A, and Hermes 4A cell lines were obtained from the Wellcome Trust Functional Genomics
Cell Bank and cultured as instructed [37,38]. (c) Cytotoxicity of compound 11 in comparison to
APE/Ref−1 inhibitors E2009 and E3330 in A375 melanoma cells. (d) Melanoma cells are more
sensitive to compound 11 in comparison to melanoblast Hermes 1 cells.

2.5. Compound 2 Suppressed H2 O2 -Induced AP-1 Transactivation in Human Melanoma Cells
An AP-1 transactivation assay was conducted in melanoma cells transfected with a luciferase reporter construct as described previously [39]. Our study showed that compound
2 at 0.5 µM effectively inhibited AP-1 transactivation induced by H2 O2 in A375 melanoma
cells compared with H2 O2 alone (p < 0.05) (Figure 4). The H2 O2 -activated AP-1 activity was
reduced from 2.3-fold of control to approximately basal levels (95.7% of control); however,
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compound 2 did not display any inhibition of the basal AP-1-dependent transcription.
Co-treatment with E3330, an APE/Ref-1 redox inhibitor, at 10 µM concentration, reduced
AP-1 activity marginally. Compound 11 at 10 µM also failed to inhibit H2 O2 -activated AP-1
transactivation (p > 0.05).

Figure 4. Inhibition of AP-1 transcriptional activation in human melanoma A375 cells by compound
2. A375 cells were transfected with an AP-1 luciferase reporter plasmid. 24 h after transfection, cells
were incubated with H2 O2 (100 µM) in the presence or absence of compound 2 (0.5 µM), compound
11 (10 µM), or E3330 (10 µM) for 48 h. After treatment, the cells were harvested to determine the
luciferase activity, expressed as fold of control without treatment. The results normalized by cell
numbers represent means ± SD of triplicates. * p < 0.05 compared to control; # p < 0.05 compared to
H2 O2 treatment.

2.6. Effects of APE/Ref-1 Inhibitor on Tumor Growth Using a Melanoma Xenograft Mouse Model
Given the limited water solubility, lead compound 2 (stocked in DMSO) was further
diluted in normal saline. The drug suspension was sonicated at room temperature for
15 min before injection to nude mice. HPLC analysis shows no evidence of chemical
structural change after compounding. The drug suspension was made fresh daily and
injected into mice immediately after compounding. The control group was intraperitoneally
injected (IP) with vehicle (0.1% DMSO in normal saline) daily based on the body weight
(0.1 mL/10 g).
As shown in Figure 5, the study demonstrated that the APE/Ref-1 inhibitor, compound
2, effectively inhibited tumor growth in vivo. The effective dose of compound 2 was as
low as 5 mg/kg IP daily without producing any apparent systemic toxicities (Figure S27,
Supplementary Materials). After 21-days of treatment, tumor growth was significantly
inhibited, with the average tumor size reduced to 58.5% of control (p < 0.05) (Figure 5a).
The average tumor weight in the treatment group was only 64.7% of that of the control
group (p < 0.05) (Figure 5b). Future studies are warranted to determine the dose-response
and pharmacokinetic profile.
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Figure 5. Compound 2 inhibited the tumor growth of human melanoma in vivo. Metastatic melanoma
A375 cells were injected into male nude mice subcutaneously on the flank. Compound 2 treatment
(5 mg/kg, IP, daily) inhibited tumor growth (a) and reduced tumor weight (b). (a) Tumor volume
was measured by digital calipers and determined using the formula (mm3 ) = (L × W2 )/2. Tumor
growth was presented as a fold increase in size from day 3 (mean ± SD). (b) Comparison of measured
tumor burden (via weight) after 21 days of therapy. The p values were determined using a two-tailed
Student’s t-test. * p < 0.05 compared to control group.

3. Discussion
In recent years, there have been dramatic developments in the treatment of advanced
cutaneous melanoma (CM) using revolutionary immunotherapy, which is a powerful
new approach yielding remarkable and durable responses in melanoma patients [40,41];
however, these checkpoint inhibitors are mainly indicated for patients with metastatic
melanoma and disease progression following other treatments [42]. In addition, current
and novel approaches have not slowed the worldwide melanoma epidemic, and the
incidence of CM continues to rise in the United States [2]. As such, the development
of novel therapeutic interventions to block melanomagenesis and disease progression to
advanced stages will have both high impact and importance.
It has been well studied that APE/Ref-1 serves as an important mechanism facilitating cancer cell survival from oxidative stresses associated with radiation therapy and
chemotherapy [15,20,43]. Novel APE/Ref-1 inhibitors have been shown to inhibit cancer
cell metastasis and the development of drug resistance, suggesting that targeting APE/Ref-1
is a promising strategy to achieve a better clinical benefit for cancer patients [17,22,30,44].
In recent years, increasing efforts have been devoted to developing novel redox inhibitors
of APE/Ref-1 for cancer treatment; however, to the best of our knowledge, only a limited
number of compounds exhibit promising APE/Ref-1 inhibitory effects [24,30,43,45,46]. A
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recently developed small molecular inhibitor of apurinic/apyrimidinic (AP) endonuclease
activity was shown to exacerbate the oxidative DNA damage following exposure to cisplatin
at 10 µM [24,25]. To date, the most successful APE/Ref-1 redox inhibitors reported are
E3330 (APX3330) and its analogs, which exhibited therapeutic effects on tumor angiogenesis
and growth without interfering with its DNA repair activities [36,47]. E3330 was also
shown to reduce the collective cell migration of human breast cancer cells and decrease
chemo-invasion and colony formation when combined with docetaxel; however, such
inhibitory activity was only evident at a higher concentration (50 µM) [30]. A recent Phase
I trial of E3330 reported that six of nineteen cancer patients had disease stabilization for
≥4 cycles after treatment [23,28]. One melanoma patient presented with a stable disease
with 245 days of treatment.
Beyond these studies, there has been little work on structure-based inhibitor design.
As detailed in our previous studies [15,17], the redox function of APE/Ref-1 plays a vital
role in melanoma progression, which is also consistent with other groups’ observation of
the anti-tumor activity of APE/Ref-1 redox inhibitors. We, therefore, selected the structure
of the redox domain of APE/Ref-1 for screening and molecular modeling. In our study, we
carried out virtual screenings using the ICM-Pro software package developed by MolSoft
L.L.C [33,34]. The program uses an energetic scoring function to carry out virtual docking
of molecules from a large database and ranks binding. Notably, the software incorporates
ligand flexibility. We screened multiple drug libraries containing over 3-million compounds
and identified the top-ranked candidate compounds. After chemical structure optimization
and cell-based bioactivity screening, we have successfully developed our lead APE/Ref-1
inhibitor, compound 2, for further structure-activity studies.
More analogs of compound 2 were synthesized to develop the structure-activity relationship and improve the physicochemical properties. Our study demonstrated that
incorporating one or two hydroxyl groups on the aromatic ring enhances the water solubility, but this comes at the expense of reducing anti-melanoma activity. Compound 11 was
found to be more water-soluble than compound 2 and exhibited promising anti-melanoma
activities compared to the reported APE-Ref-1 inhibitors, E3330 and E2009. Inhibition of
cell viability was evident even at very low concentrations in vitro (<0.1 µM). Our in vivo
mouse study showed that compound 2 treatment significantly inhibited tumor growth in a
melanoma xenograft mouse model.
However, given the hydrophobic nature of compound 2, its water solubility is limited,
and increased precipitation was evident at concentrations above 2.5 µM. Shortening the
chain from C12 to C6 markedly improved the compound’s water solubility, but significantly
reduced the anti-melanoma activity. One hypothesis is that the long-chain may contribute
to binding by facilitating or stabilizing the interaction between the compound and the
APE/Ref-1 protein. Shortening the chain may lead to an unstable binding profile and
subsequent reduction of anti-tumor activity. This hypothesis may apply to compound 12 as
well, which possesses a shortened chain and loss of anti-melanoma activity. To improve the
bioavailability and drug delivery to melanoma cells, we will also consider using a cyclic
peptide drug delivery system containing arginine and tryptophan residues developed by
the Parang group [48]. These cell-penetrating peptides were shown to effectively enhance
the uptake of anti-cancer drugs in tumor cells [49].
Structure-based virtual screening and docking have been widely used for drug discovery, such as in hit identification and lead optimization. As noted in Table 1, the virtual
docking score of a candidate compound does not always align with its anti-melanoma
activities. The poor water solubility of compound 2 significantly hindered the detection of
direct interactions between compound 2 and the APE/Ref-1 protein using Surface Plasmon
Resonance (SPR) analysis. Future crystallization studies of APE/Ref-1 protein-ligand complexes are warranted to optimize and refine the virtual modeling and ultimately improve
structure-based drug design.
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4. Materials and Methods
4.1. Materials
Trans-cinnamoyl chloride, trans-4-hydroxycinnamic acid, trans-cinnamic acid, 1,6hexamethylenediamine, 1,12-dodecamethylenediamine, all solvents, chemicals reagents,
and HPLC-eluents were purchased from Sigma-Aldrich, St. Louis, MO, USA, and used as
received without further purification. Analytical HPLC was used to confirm the purity of
final products (≥95%). The analytical HPLC was conducted on the Shimadzu RP-HPLC
system and C18 column (250 cm × 4.60 mm) over 80 min using water (0.1% TFA) as eluent
A and acetonitrile (0.1% TFA) as eluent B. NMR spectra were recorded on a Bruker Avance
III HDTM 400 NMR spectrometer using DMSO-d6 or CD3 OD as solvents and TMS as an
internal reference. Mass spectra were obtained by a Bruker Impact 11, UHR-qTOF.
4.2. Chemical Synthesis
(2E,2’E)-N,N’-(Dodecane-1,12-diyl)bis(3-phenylacrylamide)(Bis-cinnamoyl-1,12-dodecamethy
lenediamine) (2). Trans-cinnamoyl chloride (1, 100 mg, 0.6 mmol) was dissolved in dry THF
(15 mL), followed by the addition of potassium carbonate (166 mg, 1.2 mmol, 2 equiv). A
solution of 1,12-dodecamethylenediamine (60 mg, 0.3 mmol, 0.5 equiv) in THF (10 mL)
was added dropwise over 20 min and the reaction mixture was stirred for 4 h. After the
completion of the reaction, the crude product was collected by filtration, washed with
water, and crystallized from methanol to afford compound 2 as a white solid (125 mg, 45%).
The purity was confirmed by analytical HPLC (Rt = 26.69 min).
1 H NMR (400 MHz, DMSO-d ): δ (ppm) 1.20–1.31 (br s, 16H, -(CH ) ), 1.40–1.49
6
2 8
(m, -CH2 -CH2 -NH, 4H), 3.12–3.19 (m, -CH2 NH2 , 4H), 6.61 (d, J = 16 Hz, -CO-CH=CH,
2H), 7.41–7.56 (m, aromatic hydrogens, CH=CHCO, 12H), 8.19 (t, J = 5 Hz, 2H, 2NH);
13 C NMR (100 MHz, DMSO-d ): δ (ppm) 165.22 (2 C=O), 138.79 (CH=CHCO), 135.44
6
(CH=CHCO), 129.82 (aromatic C), 129.39 (aromatic C), 127.92 (aromatic C), 122.85 (aromatic
C), 26.90–29.60 (aliphatic CH2 ); HR-MS (ESI-qTOF) (m/z) (C30 H40 N2 O2 ): calcd 460.3090,
found 461.3675 [M + H]+ , 483.3516 [M + Na]+ , and 499.3270 [M + K]+ .
(2E,2’E)-N,N’-(Dodecane-1,12-diyl)bis(3-(4-hydroxyphenyl)acrylamide (4). To a solution of
4-hydroxycinnamic acid (3, 100 mg, 0.6 mmol) in DMF (20 mL) was added N-methylmorpho
line (NMM, 124 µL, 1.2 mmol, 2 equiv) followed by 1-[bis(dimethylamino)methylene]-1H1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU, 114 mg, 0.3 mmol,
0.5 equiv). The mixture was stirred at room temperature for 20 min, followed by the addition of 1,12-dodecamethylene diamine (60 mg, 0.3 mmol, 0.5 equiv). After 4 h, the solvent
was evaporated, and the resulting crude solid was loaded onto silica gel and purified via
chromatography using ethyl acetate:methanol as 90:10 (v/v), to provide compound 4 as a
white powder (95 mg, 32%). The purity was confirmed by analytical HPLC (Rt = 21.89 min).
1 H NMR (400 MHz, DMSO-d ): δ (ppm) 1.20–1.32 (br s, 16H, -(CH ) ), 1.37–1.48
6
2 8
(m, 4H), 3.10–3.19 (m, -CH2 NH2 , 4H), 6.42 (d, J = 15 Hz, -CO-CH=CH, 2H), 6.78–7.37 (m,
aromatic hydrogens, CH=CHCO, 10H), 7.95 (t, J = 5 Hz, 2H, 2NH), 9.81 (s, 2H, 2OH).
13 C NMR (100 MHz, DMSO-d6): δ (ppm) 165.69 (2 C=O), 159.21 (2C-OH), 138.89 (Alkene
carbons), 129.59 (aromatic C), 126.43 (aromatic C), 119.30 (aromatic C), 116.18 (aromatic
C), 26.96–29.68 (aliphatic CH2 ); HR-MS (ESI-qTOF) (m/z) (C30 H40 N2 O4 ): calcd 492.2988,
found 493.3185 [M + H]+ , 515.3227 [M + Na]+ , 531.2753 [M + K]+ .
(2E,2’E)-N,N’-(Hexane-1,6-diyl)bis(3-(4-hydroxyphenyl)acrylamide) (5). The same synthetic procedure as used in the synthesis of compound 4 is used in the synthesis of compound 5. 4-Hydroxycinnamic acid (3, 100 mg, 0.6 mmol), 1,6-diaminohexane (35 mg,
0.3 mmol, 0.5 equiv), HATU (114 mg, 0.3 mmol, 0.5 equiv), and N-methylmorpholine
(124 µL, 1.2 mmol, 2 equiv) were used for the synthesis. The crude product was purified by
silica gel column chromatography, using ethyl acetate: methanol as 90:10 (v/v), affording a
white product (5, 80 mg, 32%).
1 H NMR (400 MHz, DMSO-d ): δ (ppm) 1.26–1.35 (br s, 4H, -(CH ) ), 1.39–1.49 (m,
6
2 2
4H, -CH2 -CH2 -NH), 3.10–3.20 (m, -CH2 NH2 , 4H), 6.44 (d, J =16 Hz, -CO-CH=CH, 2H),
6.82–7.41 (m, aromatic hydrogens, CH=CHCO, 10H), 7.99 (t, J = 6 Hz, 2H, 2NH), 9.84 (s, 2H,
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2OH); 13 C NMR (100 MHz, DMSO-d6 ): 165.70 (2 C=O), 159.21 (2 C-OH), 138.91 (Alkene
carbons), 129.60 (aromatic C), 126.43 (aromatic C), 119.30 (aromatic C), 116.10 (aromatic
C), 26.60–29.70 (aliphatic CH2 ). HR-MS (ESI-qTOF) (m/z) (C24 H28 N2 O4 ): calcd 408.2049,
found 409.2243 [M + H]+ , 431.2371 [M + Na]+ .
(2E,2’E)-N,N’-(dodecane-1,12-diyl)bis(3-(3-hydroxyphenyl)acrylamide) (7). The synthetic
procedure is the same as the procedure used to synthesize compounds 4 and 5. 3-Hydroxyci
nnamic acid was used instead of 4-hydroxycinnamic acid. In brief, 3-hydroxycinnamic acid
(6, 100 mg, 0.6 mmol), 1,12-dodecamethylenediamine (60 mg, 0.3 mmol, 0.5 equiv), HATU
(114 mg, 0.3 mmol, 0.5 equiv), N-methylmorpholine (124 µL, 1.2 mmol, 2 equiv) were used
for the synthesis. The crude product was purified by silica gel column chromatography,
using ethyl acetate: methanol as 90:10 (v/v), affording a white product (7, 110 mg, 37%).
The purity was confirmed by analytical HPLC (Rt = 22.19 min).
1 H NMR (400 MHz, CD OD): δ (ppm) 1.23–1.36 (br s, 16H, -(CH ) ), 1.48–1.56 (m, 4H,
3
2 8
-CH2 -CH2 -NH), 3.20–3.25 (m, -CH2 NH2 , 4H), 6.53 (d, J =15 Hz, -CO-CH=CH, 2H), 6.80–7.46
(m, aromatic hydrogens, CH=CHCO, 10H); 13 C NMR (100 MHz, CD3 OD): δ (ppm) 167.24
(2 C=O), 157.61 (2 C-OH), 140.30 (CH=CHCO), 136.25 (CH=CHCO), 120.38 (aromatic C),
118.89 (aromatic C), 116.47 (aromatic C), 113.70 (aromatic C), 39.20 (CH2 NH), 26.60–29.25
(alphantic CH2 ); HR-MS (ESI-qTOF) (m/z) (C30 H40 N2 O4 ): calcd 492.2988, found 493.3168
[M + H]+ , 515.2990 [M + Na]+ , 531.2733 [M + K]+ .
(E)-N-(12-Aminododecyl)-3-(3-hydroxyphenyl) acrylamide (8). 3-Hydroxycinnamic acid
(6, 200 mg, 1.2 mmol), was added to equimolar amounts of 1,12-dodecamethylenediamine
(244 mg, 1.2 mmol) and (2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU, 455 mg, 1.2 mmol, 1 equiv), in DMF (20 mL), followed by the addition
of N,N-diisopropylethylamine (DIPEA, 417 µL, 2.4 mmol, 2 equiv) and stirring at room temperature for 3 h. The crude compound was subjected to silica gel column chromatography
for purification, using ethyl acetate:methanol:ammonia as 73:25:2 (v/v/v), to give a white
product (8, 115 mg, 27%). The purity was confirmed by analytical HPLC (Rt = 19.09 min).
1 H NMR (400 MHz, DMSO-d ): δ (ppm) 1.20–1.35 (br s, 16H, -(CH ) ), 1.40–1.58
6
2 8
(m, 4H, -CH2 -CH2 -NH), 2.68–2.81 (m, 2H, CH2 NH2 ), 3.10–3.21 (m, 2H, NHCH2 ), 6.55 (d,
J = 16 Hz, -CO-CH=CH, 1H), 6.76–7.32 (m, aromatic hydrogens, CH=CHCO, 5H), 7.69 (s,
2H, NH2 ), 8.08 (t, J = 6 Hz, 1H, NH), 9.57 (s, 1H, OH); 13 C NMR (100 MHz, DMSO-d6 ):
δ (ppm) 164.25 (2 C=O), 158.17(C-OH), 138.99 (CH=CHCO), 136.69 (CH=CHCO), 130.37
(aromatic C), 122.58 (aromatic C), 119.07 (aromatic C), 117.03 (aromatic C), 114.12 (aromatic
C), 22.50–29.65 (-CH2 ). HR-MS (ESI-qTOF) (m/z) (C21 H34 N2 O2 ): calcd 346.2620, found
347.0936 [M + H]+ .
(E)-N-(12-Cinnamamidododecyl)-3-(3-hydroxyphenyl) acrylamide (9). The synthetic procedure is the same as the one used in synthesis of compound 5 using instead N-(12aminododecyl)-3-(3-hydroxyphenyl) acrylamide (8, 50 mg, 0.14 mmol), trans-cinnamic acid
(1, 20 mg, 0.14 mmol), HATU (27 mg, 0.07 mmol, 0.5 equiv), and N-methylmorpholine
(29 µL, 0.28 mmol, 2 equiv). The crude compound was subjected to silica gel column
chromatography to purify the crude product, using methylene chloride:ethylacetate as
70:30 (v/v) to yield 9 (35 mg, 50%). The purity was confirmed by analytical HPLC
(Rt = 23.94 min).
1 H NMR (400 MHz, DMSO-d ): δ (ppm) 1.30–1.32 (br s, 16H, -(CH ) ), 1.38–1.50
6
2 8
(m, 4H, -CH2 -CH2 -NH), 3.09–3.20 (m, -CH2 NH2 , 4H), 6.50 (d, J = 16 Hz, -CO-CH=CH,
1H), 6.59 (d, J = 16 Hz, -CO-CH=CH, 1H), 6.76–7.55 (m, aromatic hydrogens, CH=CHCO,
11H), 8.02–8.10 (m, 2H, 2NH), 9.55 (s, 1H, OH). 13 C NMR (100 MHz, DMSO-d6 ): δ (ppm)
165.23 (C=O), 165.22 (C=O), 158.14 (C-OH), 138.98 (CH=CHCO), 138.79(CH=CHCO), 136.71
(CH=CHCO), 135.45 (CH=CHCO), 130.37 (aromatic C), 129.81 (aromatic C), 129.38 (aromatic C), 127.91 (aromatic C), 122.85 (aromatic C), 122.59 (aromatic C), 119.08 (aromatic C),
117.02 (aromatic C), 114.11 (aromatic C), 26.90–29.62 (aliphatic -CH2 ); HR-MS (ESI-qTOF)
(m/z) (C30 H40 N2 O3 ): calcd 476.3039, found 477.3245 [M + H]+ , 499.3068 [M + Na]+ .
N-(12-Aminododecyl)cinnamamide (10). HBTU (507 mg, 1.34 mmol, 1 equiv) was
added to equimolar amounts of trans-cinnamic acid (1, 200 mg, 1.34 mmol) and 1,12-
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dodecamethylenediamine (268 mg, 1.34 mmol, 1 equiv) in DMF (20 mL), followed by the
addition of DIPEA (465 µL, 2.4 mmol, 2 equiv) and stirring at room temperature for 3 h.
After completion of the reaction, the solution was evaporated. The white residue powder
was subjected to silica gel column chromatography, using ethyl acetate:methanol:ammonia
as 75:23:2 (v/v/v) to give the desired product (10) (110 mg, 25%). The purity was confirmed
by analytical HPLC (Rt = 20.28 min).
1 H NMR (400 MHz, DMSO-d ): δ (ppm) 1.21–1.32 (br s, 16H, -(CH ) ), 1.39–1.55 (m,
6
2 8
4H, -CH2 -CH2 -NH), 2.74 (t, J = 8 Hz, 2H, CH2 NH2 ), 3.18 (q, J = 7 Hz, 2H, NHCH2 ), 6.60 (d,
J = 16 Hz, -CO-CH=CH, 1H), 7.35–7.55 (m, aromatic hydrogens, CH=CHCO, 6H), 7.68 (s,
2H, NH2 ), 8.09 (t, J = 6 Hz, 1H, NH); 13 C NMR (100 MHz, DMSO-d6 ): δ (ppm) 165.23 (CO),
138.79 (CH=CHCO), 135.43 (CH=CHCO), 129.83 (aromatic C), 129.39 (aromatic C), 127.91
(aromatic C), 122.88 (aromatic C), 26.20–29.70 (aliphatic -CH2 ); HR-MS (ESI-qTOF) (m/z)
(C21 H34 N2 O): calcd 330.2671, found 331.3007 [M + H]+ .
(E)-N-(12-Cinnamamidododecyl)-3-(4-hydroxyphenyl) acrylamide (11). The synthetic procedure was the same as the one used for the synthesis of 5 using N-(12-aminododecyl)
cinnamamide (10, 50 mg, 0.15 mmol), 4-hydroxycinnamic acid (3, 25 mg, 0.15 mmol,
1 equiv), HATU (29 mg, 0.07 mmol, 0.5 equiv), and N-methylmorpholine (23 µL, 0.28 mmol,
2 equiv). Silica gel column chromatography was used for the purification of the crude
product with methylene chloride:ethyl acetate (70:30) (v/v) as eluents to generate compound 11 as a white product (40 mg, 55%). The purity was confirmed by analytical HPLC
(Rt = 23.68 min).
1 H NMR (400 MHz, DMSO-d ): δ (ppm) 1.15–1.33 (br s, 16H, -(CH ) ), 1.32–1.50 (m,
6
2 8
4H, -CH2 -CH2 -NH), 3.07–3.21 (m, -CH2 NH2 , 4H), 6.41 (d, J = 16 Hz, -CO-CH=CH, 1H),
6.59 (d, J = 16 Hz, -CO-CH=CH, 1H), 6.77–7.55 (m, aromatic hydrogens, CH=CHCO, 11H),
7.92 (t, J = 5 Hz, 1H, NH), 8.08 (t, J = 5 Hz, 1H, NH), 9.80 (s, 1H, OH); 13 C NMR (100 MHz,
DMSO-d6 ): δ (ppm) 164.95 (C=O), 164.20 (C=O), 159.21 (C-OH), 138.88 (CH=CHCO),
138.79 (CH=CHCO), 135.45 (CH=CHCO), 129.80 (aromatic C), 129.58 (aromatic C), 127.91
(aromatic C), 126.43 (aromatic C), 122.86 (aromatic C), 119.31 (aromatic C), 116.18 (aromatic
C), 23.50–29.70 (aliphatic -CH2 ); HR-MS (ESI-qTOF) (m/z) (C30 H40 N2 O3 ): calcd 476.3039,
found 477.3203 [M + H]+ , 499.3364 [M + Na]+ .
(2E,2’E)-N,N’-(hexane-1,6-diyl)bis(3-phenylacrylamide) (12). Hexane-1,6-diamine (0.58 g,
5 mmol), cinnamic acid (1.48 g, 10 mmol), and pyridine (15 mL) were mixed in a round
bottom flask and stirred for 15–20 min. Triphenyl phosphite (2.8 mL, 10.75 mmol) was
added to the flask, and the reaction mixture was refluxed for 8 h. Pyridine was distilled out
after cooling the mixture to room temperature to reduce the volume to 5 mL. The mixture
was left for overnight standing. After acetone was added, the obtained solid product was
filtered and washed with acetone. Methanol was used for the recrystallization of the crude
product (1.32 g, 70%). M.P. 192 ◦ C.
1 H NMR (400 MHz, DMSO-d ): δ 1.33 (s, 4H, CH ); 1.47 (s, 4H, -CH -CH -NH), 4.15 (q,
2
2
2
6
4H, J = 19.4 Hz, -CH2 NH2 ), 6.63 (d, J = 15.8 Hz, 2H, Olefin proton), 7.35–7.43 (m, 4H, Olefin
protons and Ph-H); 7.52 (m, 8H, PhH); 8.10 (s, 2H, NH). 13 C NMR (400 MHz, DMSO-d6 )
δ 165.30 (2 C=O), 138.81 (CH=CHCO), 135.42 (CH=CHCO), 129.88 (aromatic C), 129.39
(aromatic C), 127.92 (aromatic C), 122.85 (aromatic C), 39.09 (CH2 NH), 29.6 (-CH2 ), 26.7
(-CH2 ), HR-MS (ESI-qTOF) (m/z) (C24 H29 N2 O2 ): calcd 376.2151, found 377.2240 [M + H]+ .
4.3. Three-Dimensional Virtual Docking Using Molsoft ICM-Pro System
The in silico molecular docking was performed using Molsoft ICM-Pro (x64) [33]. The
druggable binding cavity located in the redox-regulatory domain of the APE/Ref-1 protein
(1BIX, 10.2210/pdb1BIX/pdb) was identified and used for docking. The molecular docking
conformation presenting the lowest binding energy was selected to visualize the possible
compound-protein interaction. The virtual docking scores were collected and the ligands
with lower observed ICM scores were chosen due to the higher chance of the ligand being
a binder to the APE/Ref-1 cavity [50].

Molecules 2022, 27, 2672

15 of 19

4.4. Cell Lines and Cell Culture
Human malignant melanoma cells (A375, #CRL-1619; SK-Mel-28, #HTB-72) were
purchased from ATCC. Cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM,
ATCC #30-2002; for A375 cells) or Eagles’ Minimum Essential Medium (EMEM, ATCC
#30-2003; for SK-Mel-28 cells) supplemented with 10% fetal bovine serum (FBS, ATCC
#30-2020) at 37 ◦ C in 5% CO2 . All cell lines were passaged once reaching 70–90% confluence.
Human immortalized melanoblast cell lines Hermes 1, Hermes 3A, and Hermes
4A were obtained from the Wellcome Trust Functional Genomics Cell Bank, generously
supplied to researchers [38]. Cells were cultured in the medium as recommended containing
RPMI 1640, FBS (10%), 12-O-tetradecanoyl phorbol acetate (TPA, 200 nM), Cholera toxin (CT,
200 pM), human stem cell factor (hSCF, 10 ng/mL), and endothelin 1 (EDN1, 10 nM) [51].
4.5. In Vitro Anti-Melanoma Activity Screening Using MTT Colorimetric Assay
Cell viability analysis was conducted based on the bio-reduction of a tetrazolium
compound (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)2H-tetrazolium) (MTT) metabolized by live cells. Briefly, human melanoma cells were
inoculated into 96 well microtiter plates in 100 µL at plating densities ranging from
5000 to 8000 cells/well depending on the doubling time of individual cell lines (A375:
5000 cells/well; Sk-Mel-28: 7500 cells/well; Hermes: 8000 cells/well). After cell inoculation, the microtiter plates are incubated for 24 h prior to the addition of experimental
drugs. Various drugs dissolved in DMSO were added to a serum-free medium at different concentrations and incubated for 72 h, and negative controls were treated with the
equivalent amounts of the DMSO solution. By the end of treatment, MTT solution was
added to the wells to a final concentration of 0.5 mg/mL for an additional 2 h incubation.
Solubilization solution (4 mM HCl, 0.1% NP-40 in isopropanol) was then added, and the
absorbance was recorded at 595 nm on a plate reader (BioRad, Hercules, CA, USA). All
readings were compared to the control, which represented 100% viability. Each experiment
was performed in triplicate and independently repeated at least two times.
4.6. Luciferase Assay to Determine AP-1 Transactivation Activities
3 × AP1pGL3 (3 × AP-1 in pGL3-basic) was a gift from Alexander Dent (Addgene
plasmid #40342), which contains three canonical AP-1 binding sites (TGACTCA) upstream
of a minimal promoter fragment containing a TATA box in the luciferase reporter plasmid
pGL3-basic [39]. 3 × AP1pGL3 was transfected to human melanoma A375 cells using
Lipofectamine 2000 following the manufacturer’s instructions (Invitrogen). 24 h after
transfection, the cells were treated with H2 O2 (100 µM) for 48 h in the presence or absence
of APE/Ref-1 inhibitors (10 µM).
After different treatments, the cells were rinsed twice with phosphate-buffered saline
(PBS). Cells were then scraped from the plates in PBS and pelleted for 4 min at 4 ◦ C in a
microcentrifuge at 12,000 rpm. Cell pellets were resuspended in 100 µL luciferase lysis
buffer as per manufacturer instructions (Promega, #E1500). Luciferase activity measured in
relative light units reflects the AP-1 transcription rate and was detected by a SpectraMax
M5 UV VIZ Plate Reader. A cell count was conducted for normalization. All samples were
studied in duplicate, and readings were taken in triplicate. Each experiment was repeated
at least two times.
4.7. In Vivo Xenograft Melanoma
The Institutional Animal Care and Use Committee approved all the animal procedures
at Chapman University (IACUC #2020-1131). Male nude mice (Nu/Nu) were purchased
from Charles River (Wilmington, MA, USA) and were housed and maintained in the Chapman University vivarium under pathogen-free conditions. Human metastatic melanoma
A375 cells were injected subcutaneously into the flank (1 × 106 cells per mouse). Three
days-post tumor cell injection, mice were randomized into different groups. The treatment
group was injected with compound 2 (5 mg/kg/day, IP) for 21 days. The growth of the
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tumors was monitored three times a week and measured using digital Vernier calipers. The
size of the tumors was calculated as tumor volume (mm3 ) = (L × W2 )/2. The mice were
sacrificed at the end of the study via CO2 euthanasia and cervical dislocation.
5. Conclusions
The novel APE/Ref-1 inhibitor developed in our study (compound 2) showed promising anti-melanoma activities in vitro and in vivo, suggesting that targeting APE/Ref-1mediated signaling might be a novel and effective strategy for melanoma therapy. More
studies are warranted in the future to develop more bioavailable and potent APE/Ref-1
inhibitors with chemical modifications of the lead compound.
Supplementary Materials: The following supporting information can be downloaded at: https:
//www.mdpi.com/article/10.3390/molecules27092672/s1, Analytical HPLC profile of representative
compounds; Figure S1: 1 H NMR (400 MHz, DMSO-d6 ) of (2E,2’E)-bis-cinnamoyl-1,12-dodecamethyle
nediamine (2); Figure S2: 13 C NMR (100 MHz, DMSO-d6 ) of (2E,2’E)-bis-cinnamoyl-1,12-dodecamethy
lenediamine (2); Figure S3: Mass spectra of (2E,2’E)-bis-cinnamoyl-1,12-dodecamethylenediamine
(2); Figure S4: 1 H NMR (400 MHz, DMSO-d6) of (2E,2’E)-N,N’-(dodecane-1,12-diyl)bis(3-(4 hydroxyphenyl)acrylamide (4); Figure S5: 13 C NMR (100 MHz, DMSO-d6 ) of (2E,2’E)-N,N’-(dodecane-1,12diyl)bis(3-(4-hydroxyphenyl) acrylamide (4); Figure S6: Mass spectra of (2E,2’E)-N,N’-(dodecane-1,12diyl)bis(3-(4-hydroxyphenyl) acrylamide (4); Figure S7: 1 H NMR (400 MHz, DMSO-d6 ) of (2E,2’E)N,N’-(hexane-1,6-diyl)bis(3-(4-hydroxyphenyl)acrylamide) (5); Figure S8: 13 C NMR (100 MHz, DMSOd6 ) of (2E,2’E)-N,N’-(hexane-1,6-diyl) bis(3-(4-hydroxyphenyl) acrylamide) (5); Figure S9: Mass
spectra of (2E,2’E)-N,N’-(hexane-1,6-diyl) bis(3-(4-hydroxyphenyl) acrylamide) (5); Figure S10: 1 H
NMR (400 MHz, DMSO-d6 ) of (2E,2’E)-N,N’-(dodecane-1,12-diyl)bis(3-(3 hydroxyphenyl)acrylamide)
(7); Figure S11: 13 C NMR (100 MHz, DMSO-d6 ) of (2E,2’E)-N,N’-(dodecane-1,12-diyl) bis(3-(3hydroxyphenyl) acrylamide) (7); Figure S12: Mass spectra of (2E,2’E)-N,N’-(dodecane-1,12-diyl)
bis(3-(3-hydroxyphenyl) acrylamide) (7); Figure S13: 1 H NMR (400 MHz, DMSO-d6 ) of (E)-N-(12aminododecyl)-3-(3-hydroxyphenyl) (8); Figure S14: 13 C NMR (100 MHz, DMSO-d6 ) of (E)-N-(12aminododecyl)-3-(3-hydroxyphenyl) (8); Figure S15: Mass spectra of (E)-N-(12-aminododecyl)-3-(3hydroxyphenyl) (8); Figure S16: 1 H NMR (400 MHz, DMSO-d6 ) of (E)-N-(12-cinnamamidododecyl)3-(3-hydroxyphenyl) acrylamide (9); Figure S17: 13 C NMR (100 MHz, DMSO-d6 ) of (E)-N-(12cinnamamidododecyl)-3-(3-hydroxyphenyl) acrylamide (9); Figure S18: Mass spectra of (E)-N-(12cinnamamidododecyl)-3-(3-hydroxyphenyl) acrylamide (9); Figure S19: 1 H NMR (400 MHz, DMSOd6) of N-(12-aminododecyl) cinnamamide (10); Figure S20: 13 C NMR (100 MHz, DMSO-d6 ) of
N-(12-aminododecyl) cinnamamide (10); Figure S21: Mass spectra of N-(12-aminododecyl) cinnamamide (10); Figure S22: 1 H NMR (400 MHz, DMSO-d6 ) of (E)-N-(12-cinnamamidododecyl)-3-(4hydroxyphenyl) (11); Figure S23: 13 C NMR (100 MHz, DMSO-d6) of (E)-N-(12-cinnamamidododecyl)3-(4-hydroxyphenyl) (11); Figure S24: Mass spectra of (E)-N-(12-cinnamamidododecyl)-3-(4-hydroxyp
henyl) (11); Figure S25: 1 H NMR (400 MHz, DMSO-d6 ) of (2E,2’E)-N,N’-(hexane-1,6-diyl)bis(3phenylacrylamide) (12); Figure S26: 13C NMR (100 MHz, DMSO-d6) of (2E,2’E)-N,N’-(hexane1,6-diyl)bis(3-phenylacrylamide) (12); Figure S27: No significant reduction of body weight was
evident in mice treated with compound 2 (5 mg/kg, IP , daily) for 21 days in a melanoma xenograft
mouse model.
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